Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bronchodilator Agents

Criteria

Inclusion Criteria:

• Cigarette smoking history-Current or ex-smokers (defined as stopped smoking for at least three months prior to the study visit)

• Established history of COPD as diagnosed by a physician

• Regular use (prescribed for use every day) of only one long-acting bronchodilator greater than or equal to one month before the study visit

• Ability to read, comprehend, and record information in the English language

Exclusion Criteria:

• Currently active asthma (receiving asthma therapy and or having asthma symptoms)

• Use of ipratropium/albuterol combination products greater than three times per day, use of inhaled corticosteroids, use of inhaled corticosteroid/long-acting beta-agonist combinations, theophylline preparations, or oral beta agonists within 3 months prior to the study visit

• Previous lung surgery

• Other respiratory disorders other than COPD

• Current alcohol, illegal drug, or solvent abuse

• Females with a positive urine pregnancy test at the study visit